Drug Development in Psychiatry

The book reviews clinical trial methodology in drug development in psychiatry, covering the history from serendipitous discovery to targeted approaches, with a focus on novel drugs and disease targets. It discusses how biomarkers, genetics, and neuroscience have influenced methodology and the future of drug development in psychiatry.

Format: Hardback
Length: 459 pages
Publication date: 17 March 2023
Publisher: Springer International Publishing AG

The book delves into the intricate realm of clinical trial methodology as it pertains to drug development in psychiatry, offering a comprehensive and insightful exploration. Through the use of clinically relevant examples, the reader gains a deep understanding of the entire process, from the initial stages of discovery through the final stages of marketing. This journey encompasses the historical backdrop of drug development in psychiatry, spanning from the era of serendipitous discoveries to the present era characterized by the pursuit of novel and highly focused targets. Readers will be captivated by the evolution of drug development in psychiatry, as it has adapted and transformed in response to the discovery of novel mechanisms of action drugs.

Moreover, the book sheds light on the significant impact of novel drugs and disease targets on clinical trial methodology. It highlights how these advancements have reshaped the way developers and regulatory agencies approach clinical trials, leading to innovative approaches and improved outcomes.

The book is organized into three distinct sections, each providing valuable insights into different aspects of drug development in psychiatry.

Section A: Prior to the 1960s
In this section, the book delves into the early days of drug discovery in psychiatry. It explores how drugs were initially discovered through chance observations and anecdotal evidence. It highlights the pioneering work of individuals such as Carl Wernicke and Paul Ehrlich, who made significant contributions to the field.

Section B: The Last 50 Years
The second section focuses on the last 50 years of drug development in psychiatry. It examines how the field has refined its targeting of CNS drugs without the discovery of mechanistically new drugs. It discusses the development of new drug delivery systems, such as transdermal patches and injectable formulations, as well as the use of biomarkers and genetics to improve drug efficacy and safety.

Section C: The Future
The final section previews the future of drug development in psychiatry. It explores the discovery and development of mechanistically new drugs, which hold the promise of revolutionizing the treatment of mental disorders. It discusses the use of novel targets, genetics, and biomarkers to identify and validate new drug candidates.

In conclusion, the book is a valuable resource for researchers, clinicians, and students interested in drug development in psychiatry. It provides a comprehensive and up-to-date overview of the field, covering the historical, clinical, and scientific aspects of drug development. By exploring the influence of biomarkers, genetics, and advances in neuroscience and neuroimaging, the book offers a glimpse into the future of psychiatry and the potential for new and innovative treatments.

Weight: 863g
Dimension: 235 x 155 (mm)
ISBN-13: 9783031210532
Edition number: 1st ed. 2023